Bivalirudin CAS 128270-60-0

Introduction：Basic information about Bivalirudin CAS 128270-60-0, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Bivalirudin Basic information

• Product Name: Bivalirudin
• Synonyms: Bivalirudin, TFA;BIVALIRUDIN;BIVALIRUDIN TRIFLUOROACETATE;BITTERMELONP.E;Human Bivalirudin;DPHE-PRO-ARG-PRO-GLY-GLY-GLY-GLY-ASN-GLY-ASP-PHE-GLU-GLU-LLE-PRO-GLU-GLU-TYR-LEU;Bivalirudin Acetate;BivalirudinBG 8967, Hirulog, Hirulog I
• CAS: 128270-60-0
• MF: C98H138N24O33
• MW: 2180.29
• EINECS: 274-570-6
• Product Categories: API;proteins;Peptide;128270-60-0
• Mol File: 128270-60-0.mol

Bivalirudin Chemical Properties

• density: 1.52±0.1 g/cm3(Predicted)
• storage temp.: -20°C
• solubility: ≥54.5 mg/mL in DMSO with gentle warming; ≥10.18 mg/mL in EtOH with gentle warming and ultrasonic; ≥43.5 mg/mL in H2O with gentle warming
• form: powder
• color: white to off-white
• Sequence: D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH
• InChIKey: OIRCOABEOLEUMC-GEJPAHFPSA-N

Safety Information

• WGK Germany: 3
• HS Code: 3504009000
• Storage Class: 11 - Combustible Solids

Bivalirudin Usage And Synthesis

Anticoagulants

Bivalirudin is a kind of synthetic novel anticoagulants. It is the direct, specific and reversible inhibitor of thrombin. It was developed by the Swiss Basset (Biogen) originally. Then it was transferred to the United States Medicines Company, and approved for marketing in the United States in 2000. Its anticoagulant ingredient is a kind of 20 peptides derived from hirudin. Bivalirudin can specifically bind with catalytic site and the anion binding site of whether thrombin that is in the blood circulation or thrombus-bound thrombin, thus directly inhibiting thrombin activity. And its role is characterized by short, reversible. Early clinical studies show that the anticoagulation treatment of bivalirudin is good. And the incidence of bleeding events is low. So its use is safer than traditional heparin therapy. It is mainly used for the prevention of angioplasty interventional treatment of ischemic complications of unstable angina pectoris before and after.  

Dosage

The first dose 0.75 mg/kg is injected intravenously. Then it is continuously injected intravenously with 1.75 mg/kg per hour by percutaneous coronary intervention. ACT should be monitored after first intravenous injection for 5 minutes. If necessary, 0.3mg/kg bivalirudin is injected again. After percutaneous coronary intervention treatment, it is continued to use for 4h. If necessary, 0.2 mg/kg bivalirudin per hour is continuously injected for 20h. When it is used, using 5mL water for injection to dissolve, and then using 50 mL normal saline to be diluted to 5mg/mL solution.

Adverse reactions and precautions

1. To guard against the occurrence of bleeding, including intracranial hemorrhage, thrombocytopenia. Intravenously injection should stop immediately when a sudden drop in blood pressure and blood volume.
2. Back pain, headaches, insomnia, anxiety, abdominal pain, diarrhea, nausea, vomiting, low blood pressure can be seen. When serious bivalirudin should be discontinued. Patients with renal dysfunction should reduce its dosage.
3. Patients allergic to bivalirudin and active bleeding should be banned. Women, infants, breast-feeding women should be careful to use this product.
4. Bivalirudin cannot bind with plasma proteins and red blood cells. When bivalirudin is used with heparin, warfarin, or thrombolytic drugs, it will increase the possibility of bleeding of patients. Once the excessive use, it should be discontinued. The product can be cleared by hemodialysis.

Clinical evaluation

In order to prove the efficacy and safety of bivalirudin in the treatment of patients with acute coronary syndrome (ACS), the researchers designed the ACUITY clinical research.
ACUITY clinical trial was to compare the efficacy and safety of bivalirudin with traditional heparin platelet glycoprotein Ⅱb/Ⅲa inhibitor therapy in high-risk ACS patients. ACUITY results published in a recent issue of the "New England Journal of Medicine" showed that the efficacy of bivalirudin alone is same with traditional anticoagulant drugs. While preventing ischemic events, it can significantly reduce bleeding.
ACUITY trial chooses 13,819 patients from 17 countries with high-risk non-ST segment elevation acute coronary syndrome. Patients were randomly divided into three group: unfractionated heparin or low molecular weight heparin and glycoprotein Ⅱb/Ⅲa inhibitor combination group, bivalirudin and glycoprotein Ⅱb/Ⅲa inhibitor combination group and bivalirudin alone group. The primary endpoint is ischemic composite endpoint occurred in 30 days (death, myocardial infarction or unplanned revascularization due to ischemia), major bleeding events and overall clinical outcomes (the sum of ischemic or serious bleeding events). The results showed that compared with heparin and glycoprotein Ⅱb/Ⅲa inhibitor combination group, the incidence of ischemic events in bivalirudin alone group did not significantly increase (7.8% vs 7.3%;. P = 0.32 ). Bleeding risk decreased 47% (3.0% vs. 5.7%; P <0.001), and the overall clinical outcomes were also improved significantly (10.1% vs.11.7%; P = 0.015). Using bivalirudin alone is not inferior to the combination of heparin and glycoprotein Ⅲb/Ⅲa inhibito. In addition, the combinations of bivalirudin and glycoprotein Ⅱb/Ⅲa inhibitor are also not inferior to heparin and glycoprotein Ⅱb/Ⅲa inhibitors, but no advantage at all.
Stone, the study leader in Columbia University Medical Center Stone, believes that " for high-risk ACS patients with early intervention therapy, bivalirudin is a suitable alternative to heparin or enoxaparin when used with glycoprotein Ⅱb/Ⅲa inhibitors. Compared with the combinations of heparin and glycoprotein Ⅱb/Ⅲa inhibitors or the combinations of bivalirudin and glycoprotein Ⅱb/Ⅲa inhibitor, bivalirudin treatment can make patients to have a more significant net clinical benefit. And event-free survival in 30 days can be improved. "

Uses

Alternative medicine as ordinary heparin and platelet glycoprotein IIb/IIIa antagonists.

Description

Bivalirudin is an inhibitor of α- and ζ-thrombin (K_is = 2.56 and 1.84 nM, respectively), enzymes that exhibit high fibrinogen-clotting activities. It is selective for α- and ζ-thrombin, lacking activity at trypsin and γ-thrombin, which lacks clotting activity, at a >1,000-fold excess of bivalirudin. Bivalirudin inhibits α-thrombin-stimulated activation of the clotting factors Factor X, Factor V, and prothrombin in contact-activated plasma at a concentration of 0.1 μM. Administration of bivalirudin (0.5-1.5 mg/kg, i.v.) reduces platelet deposition in a rat carotid endarterectomy model in a dose-dependent manner. Formulations containing bivalirudin have been used to prevent ischemic events during angioplasty for thrombus-containing lesions.

Originator

Biogen (US)

Uses

Anticoagulant; antithrombotic.

Definition

ChEBI: Bivalirudin is a synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant. It has a role as an anticoagulant and an EC 3.4.21.5 (thrombin) inhibitor.

Manufacturing Process

A 20 amino acid polypeptide [1], bivalirudin (hirulog) is a synthetic version ofhirudin. Its amino-terminal D-Phe-Pro-Arg-Pro domain, which interacts withthe active site of thrombin, is linked via four Gly residues to a dodecapeptideanalogue of the carboxy-terminal of hirudin. Like hirudin, bivalirudin alsoforms a 1:1 stoichiometric complex with thrombin. Once bound, however, theArg-Pro bond at the amino-terminal of bivalirudin is cleaved by thrombin,thereby restoring active site functions of the enzyme complexes of α-thrombin[2].
Hirulog-8 has the formula: H-(D-Phe)-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH. Hirulog-8 was synthesized byconventional solid-phase peptide synthesis employing an Applied Biosystems430 A Peptide Synthesizer. This peptide was synthesized using BOC-L-Leucine-O-divinylbenzene resin. Additional t-BOC-amino acids (Peninsula Laboratories, Belmont, Calif.) used included BOC-O-2,6-dichlorobenzyl tyrosine, BOC-Lglutamicacid (γ-benzyl ester), BOC-L-proline, BOC-L-isoleucine, BOC-Lphenylalanine,BOC-L-aspartic acid (β-benzyl ester), BOC-glycine, BOC-Lasparagine,BOC-L-phenylalanine, and BOC-L-arginine. In order to achievehigher yields in synthesis, the (Gly)4 linker segment was attached in twocycles of manual addition of BOC-glycylglycine (Beckman Biosciences, Inc.,Philadelphia, Pa.). After completion of synthesis, the peptide was fullydeprotected and uncoupled from the divinylbenzene resin by treatment withanhydrous HF:p-cresol:ethylmethyl sulfate (10:1:1, v/v/v). Following removalfrom the resin, the peptide was lyophilized to dryness.
Crude Hirulog-8 was purified by reverse-phase HPLC employing an AppliedBiosystems 151A liquid chromatographic system and a Vydac C18 column(2.2x25 cm). The column was equilibrated in 0.1% TFA/water and developedwith a linear gradient of increasing acetonitrile concentration from 0 to 80%over 45 minutes in the 0.1% TFA at a flow-rate of 4.0 ml/min. The effluentstream was monitored for absorbance at 229 nm and fractions were collectedmanually. We purified 25-30 mg of crude Hirulog-8 by HPLC and recovered15-20 mg of pure peptide.
The structure of purified Hirulog-8 was confirmed by amino acid and sequenceanalyses.

Brand name

Angiomax (Medicinova).

Therapeutic Function

Anticoagulant

Biochem/physiol Actions

Bivalirudin is a specific and reversible bivalent direct thrombin inhibitor. Bivalirudin specifically binds to both the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.

Mechanism of action

Bivalirudin is a rapid-onset, short-acting DTI that binds to both the active site and the exosite-1 ofthrombin. Unlike lepirudin, bivalirudin is a reversible inhibitor of both free thrombin and thrombinbound to fibrin. This reversibility is possible because the bound bivalirudin undergoes cleavage atthe second N-terminal proline to release the portion of the drug bound to the active site. Thecarboxyl-terminal portion of bivalirudin dissociates from thrombin to regenerate thrombin. Bivalirudin does not bind to plasma protein.

Pharmacokinetics

Bivalirudin is administered via intravenous bolus injection, followed by continuous infusion (Table31.4). The drug exhibits a rapid onset and a short duration of action. Bivalirudin is eliminated byrenal excretion. It has been suggested that dosage adjustments be made in patients with severerenal impairment and in patients undergoing dialysis. Approximately 30% is eliminated unchangedalong with proteolytic cleavage products. Because of the reversible nature of bivalirudin the drugexhibits less risk of bleeding than other antithrombotics, and there have been no reported cases ofantibody formation to bivalirudin.

Clinical Use

Bivalirudin, a 20-amino-acid peptide, has been approved for use in patients with unstable anginaundergoing percutaneous coronary intervention.

Drug interactions

Potentially hazardous interactions with other drugs
Analgesics: increased risk of haemorrhage with IV diclofenac and ketorolac.
Antiplatelets and anticoagulants: increased risk of bleeding. Thrombolytics: may increase risk of bleeding complications; enhance effect of bivalirudin.

Metabolism

As a peptide, bivalirudin is expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acid in the body pool. Bivalirudin is metabolised by proteases, including thrombin. The primary metabolite resulting from the cleavage of Arg3-Pro4 bond of the N-terminal sequence by thrombin is not active because of the loss of affinity to the catalytic active site of thrombin.

Description

The active of Bivalirudin substance is a synthetic 20 amino acid peptide. The amino acid sequence is Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly- Asn-Gly-Asp-Phe-Glu-Glu-Ile- Pro-Glu-Glu-Tyr-Leu. The Mw is 2180 dalton.

Background

Bivalirudin directly inhibits thrombin by specifically binding as well to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. Bivalirudin is a specific and reversible direct thrombin inhibitor.
Thrombin, which is a serine protease, plays a central role in the thrombotic process; it cleaves fibrinogen into fibrin monomers and activates Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked structure which stabilizes the thrombus. Thrombin also activates Factors V and VIII, which promotes further thrombin generation, activates platelets, stimulating aggregation and granule release.

references

[1]. shammas n w. bivalirudin: pharmacology and clinical applications[j]. cardiovascular drug reviews, 2005, 23(4): 345-360.

Bivalirudin Preparation Products And Raw materials

• Raw materials: ethyl methyl sulfate-->hydrogen fluoride-->BOC-Glycine-->p-Cresol-->Trifluoroacetic acid-->N-(tert-Butoxycarbonyl)-L-phenylalanine-->BOC-L-Isoleucine-->Di-tert-butyl dicarbonate-->BOC-ARG-OH-->BOC-L-Asparagine-->BOC-L-Proline-->libaotao-->Hydrogen fluoride-->L-Tyrosine